Cirrhosis News and Research

Latest Cirrhosis News and Research

Isis designates ISIS-AATRx candidate in collaboration with GSK

Isis Pharmaceuticals, Inc. announced today that it has designated the second development candidate, ISIS-AATRx, in its collaboration with GlaxoSmithKline

12 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

Scripps Research receives NIH grant to determine how HCV induces liver cancer

The Scripps Research Institute has been awarded a $2.2 million grant by the National Institutes of Health (NIH) to determine how the hepatitis C virus (HCV) induces liver cancer.

11 Oct 2011

Positive results from Biotron's BIT225 Phase 2a trial on HCV

Australian drug development company Biotron Limited has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.

11 Oct 2011

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.

4 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.

1 Oct 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

Galectin Therapeutics Inc. today announced that it posted a new corporate presentation video to its website, www.galectintherapeutics.com, that highlights the Company's leadership position in developing galectin-inhibiting therapeutics to treat fibrosis and cancer.

30 Sep 2011

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Patients with non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis or cirrhosis have a lower incidence of liver-related complications and hepatocellular carcinoma (HCC) than patients infected with hepatitis C virus (HCV), according to the prospective study published in the October issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

28 Sep 2011

Liver transplantation candidates without HCC derive greater survival benefit from LDLT

New research shows liver transplantation candidates without hepatocellular carcinoma (HCC) derive a greater survival benefit from a living donor liver transplant (LDLT) than waiting for a deceased donor liver transplant.

28 Sep 2011

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first dose level received the drug and showed no signs of discomfort or other adverse effects.

19 Sep 2011

Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients

Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.

19 Sep 2011

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

Treatment with a telaprevir-based combination regimen for hepatitis C - heretofore a chronic, destructive and difficult to manage disease - effectively can be shortened to six months in about two-thirds of patients, finds a new study published Thursday in the New England Journal of Medicine.

16 Sep 2011

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK (telaprevir) tablets in people with genotype 1 chronic hepatitis C who were new to treatment.

15 Sep 2011

'Achilles' heels' within HCV virus

Hopes for an effective vaccine and treatment against the potentially fatal hepatitis C virus (HCV) have received a major boost following the discovery of two 'Achilles' heels' within the virus.

14 Sep 2011

Breakthrough opens new avenues for hep C vaccine

Hopes for an effective vaccine and treatment against the potentially fatal hepatitis C virus (HCV) have received a major boost following the discovery of two ‘Achilles’ heels’ within the virus.

12 Sep 2011

Aerobic exercise best for belly fat reduction: Study

A new study has shown that the best type of exercise to burn unhealthy belly fat is aerobic exercise. The results showed that people who did aerobics for eight months lost about 2.5 square inches of belly fat, as measured on a CT scan. That's about 1.5 times as much as people who did a combination of aerobic exercise and weight lifting, and about 20 times as much as those who only lifted weights.

31 Aug 2011

Survival for patients with HCC increases with radioembolization

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed that the procedure is likely to provide survival benefit across different tumor stages, including patients with advanced liver cancer and with limited treatment options.

23 Aug 2011

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated today announced that Health Canada has approved INCIVEK tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

23 Aug 2011

Cirrhosis News and Research

Latest Cirrhosis News and Research

Isis designates ISIS-AATRx candidate in collaboration with GSK

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Scripps Research receives NIH grant to determine how HCV induces liver cancer

Positive results from Biotron's BIT225 Phase 2a trial on HCV

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Liver transplantation candidates without HCC derive greater survival benefit from LDLT

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

'Achilles' heels' within HCV virus

Breakthrough opens new avenues for hep C vaccine

Aerobic exercise best for belly fat reduction: Study

Survival for patients with HCC increases with radioembolization

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cirrhosis News and Research

Latest Cirrhosis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in